Short answer
Pfizer Inc (PFE) filed its Q2 2025 10-Q quarterly report on Aug 5, 2025 for the quarter ended Jun 29, 2025. Quarterly revenue was $14.7B (up 10.3% year over year) with net income of $2.9B.
Q2 2025 key financials · XBRL
- Revenue
- $14.7B
- +10.3% YoY · +6.8% QoQ
- Net income
- $2.9B
- +6997.6% YoY · −1.9% QoQ
- EPS (diluted)
- $0.51
- −1.9% QoQ
Source: XBRL data from the Pfizer Inc (PFE) Q2 2025 10-Q on SEC EDGAR. USD.
Pfizer Inc Q2 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: OBBBA tax law enacted July 4, 2025, with further guidance pending, potentially impacting tax and tariff policies globally
- Material update: Reduced demand and excess inventory risk for COVID-19 products amid endemic seasonal market conditions and shifting EUA status
- Key legal risk: Ongoing evaluation of nitrosamine impurities, voluntary withdrawal of Oxbryta lots, posing regulatory and commercial uncertainties
- Operational risk: Supply disruptions at own and third-party facilities threatening manufacturing and sales continuity
- Financial risk: Potential increased leverage and credit rating downgrade from additional equity or debt financing for acquisitions and business development
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Pfizer Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.